11726 San Vicente Boulevard
518 articles about LadRx Corporation
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (CPH: ORPHA).
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy.
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx).
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that John Caloz, Chief Financial Officer, will present at the 11th Annual LD Micro Main Event on December 5, 2018 at 3:00 P.M. Pacific Daylight Time at the Luxe Sunset Boulevard Hotel in Bel-Air.
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Aldoxorubicin Is Part of the NANT Cancer Vaccine Combinations Which Include Immunotherapy and Cell-based Therapy.
Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets
Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
Aldoxorubicin Being Studied in NantCell Clinical Trials in Combination with Immune-Based Therapy for the Treatment of Squamous Cell Carcinoma, Metastatic Pancreatic and Triple Negative Breast Cancers
CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
CytRx Corporation announced that it will report financial results for the quarter ended September 30, 2018 on Friday, November 2, 2018.
CytRx Corporation today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the 2018 MicroCap Conference on Tuesday, October 2, 2018 at 3:00 P.M. Eastern Daylight Time at the Essex House in New York City.
CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
CytRx Corporation today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference.
Substantial Reduction in CytRx Cash Burn Rate This Quarter
CytRx Corporation announced that it has made the final scheduled payment under a long-term loan facility agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P.
CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended June 30, 2018 on Monday, August 6, 2018.
Breakthrough Personalized Medicine Companion Diagnostic Filed for its Albumin-binding Drug Candidates
CytRx Corporation today announced the expiration of warrants for approximately 3.2 million shares of its common stock, effective July 20, 2018.
CytRx Corporation announced that Mr. Eric Curtis, CytRx's President and Chief Operating Officer, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19 at 12:00 noon Eastern Daylight Time at Convene-Midtown West in New York, NY.
Clinical studies with aldoxorubicin demonstrated increased progression-free survival and tumor response with low cardiotoxicity
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
Data Show Aldoxorubicin, Alone or in Combination with Ifosfamide, Lacks Cardiotoxicity with Doxorubicin Equivalent Doses Beyond 1000 mg/m2
CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates
CytRx Corporation announced the formation and launch of Centurion BioPharma Corporation.